10-12 September 2018 //  Lancaster Royal Hotel, London

Interview with Dr Sven Kili

One of the big gene therapy success stories of 2016 so far has been the approval of GlaxoSmithKline’s Strimvelis by the European Commission, to treat patients with ADA-SCID.

Ahead of Phacilitate’s Cell & Gene Therapy Europe next week, we had the pleasure of talking with Dr Sven Kili, VP and Head of Cell & Gene Therapy Development at GlaxoSmithKline about the next steps now that Strimvelis has been approved, the changing model of orphan drug designation, and how the commercial supply chain strategy for Strimvelis is taking shape.


2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad